Real world study in Locally Advanced or Metastatic NSCLC patients, Progressed From First-line EGFR-TKI Therapy - PISCES

Inclusion Criteria

• 1. Male or female patients with age ≥18 years old
• 2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC patients
• 3. Patients with prior confirmed EGFR mutation-positive, who have progressed from first line EGFR-TKI*
• 4. Provision of written informed consent by the patient should be within 6 weeks of the date of progression from first line EGFR-TKI treatment
• *Note：
• a) First-line EGFR-TKI is monotherapy;
• b) EGFR-TKI has been launched in China includes first-generation, second-generation or third-generation EGFR-TKI, but not including the original chemical compound
• c) Exclude the Chinese traditional medicine that is being used to treat lung cancer
• d) Progression was determined according to Recist1.1 criteria.